Connect with us


DeepTrace Technologies: 1.7 million round for AI-based radiological imaging startup

A new round of financing was opened for the spin-off of Istituto Universitario di Studi Superiori (Iuss of Pavia), DeepTrace Technologies, which has developed over ten predictive models that process diagnostic imaging with speed and accuracy. The investment round will allow the startup to obtain CE certification for its proprietary medical devices and expand the spectrum of diseases covered by the application.



DeepTrace Technologies is an innovative startup, a spin-off of the Istituto Universitario di Studi Superiori (Iuss of Pavia), which operates in the field of artificial intelligence, combining it with medical imaging in order to make diagnoses and prognoses in a more accurate, faster and predictive way. Thus saving time which, in certain circumstances and conditions, can be extremely precious. 

The Progress Tech Transfer fund launched last year by Mito Technology has subscribed the first round of investment for $2 million (€1.7 million), acquiring a minority share, assisted by Klecha & Co as financial advisor.

If you want to find more details about the startup DeepTrace Technologies and its latest developments, download for free the Born2Invest mobile app. Our companion app brings you the most important business headlines in the world, so you can stay on top of the market. Born2Invest is available for both Android and iOS devices.

But what does DeepTrace do? 

Founded in 2018, but based on research work rooted at least in 2015, the startup has developed a radiological image analysis system based on the use of AI that improves the speed of screening, the quality of diagnosis and allows to modulate the most suitable therapy for the patient.

A solution that integrates the work of medical specialists and specialized technicians and makes it possible to predict the risk of the onset of the disease, its evolution and the possible poor response to a given therapy, thus reducing consequent healthcare costs and avoiding invasive medical tests, ineffective treatments and unnecessary care.

“The company’s approach, based on data analytics and personalized predictive medicine, enables the delivery of highly efficient, low-cost and limited-risk medical devices,” reads a note from Klecha, a private pan-European investment bank specializing in the technology, software, IT services, hardware and IoT sectors. “In less than three years, DeepTrace Technologies has developed more than 10 predictive models for various diseases, including Alzheimer’s, for different types of carcinoma and for viral diseases including, most recently, Covid-19.

The model for Covid-19 interstitial pneumonia

The company has in fact developed last spring, and in a few weeks thanks to the collaboration with a group of clinical researchers from the University of Milan Bicocca, the State University of Milan, CNR, IRCCS Policlinico San Donato and San Gerardo Hospital in Monza, a method to recognize the presence of interstitial pneumonia caused by coronavirus on the basis of a normal digital X-ray of the patient. 

A method developed by training the proprietary platform Trace4 to identify and recognize the features that differentiate the radiographic images of the lungs of individuals affected by Covid-19 from those with similar symptoms. The advantages lie in the rapidity of response, low cost and maximum versatility, as in other types of diseases.

The company aims to obtain European certification for its devices

The investment round will allow the startup, led by CEO Christian Salvatore, to obtain CE certification for its proprietary medical devices and expand the spectrum of diseases covered by the application. Not only that: a part of the resources will be dedicated to the improvement of the analysis software with the aim of making it even more complete and customizable, allowing customers to take advantage of it as much as possible.


(Featured image by auxamlech via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Smartmoney, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.

Continue Reading